![](https://monteverdelaw.com/wp-content/uploads/header-logo.png)
Pieris Pharmaceuticals, Inc. (Nasdaq: PIRS), relating to its proposed merger with Palvella Therapeutics, Inc. Under the terms of the agreement, Pieris shareholders are expected to own approximately 18% of the combined company.
Pieris Pharmaceuticals, Inc. (Nasdaq: PIRS), relating to its proposed merger with Palvella Therapeutics, Inc. Under the terms of the agreement, Pieris shareholders are expected to own approximately 18% of the combined company.